secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2025-02-11T23:59:59+00:00
Accession:  0000950170-25-017458
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics appoints Robert E. Landry to Board of Directors, effective Feb 10, 2025
--------------------------------------------------------------------------------

- Robert E. Landry appointed as Class II director, term expiring at 2027 annual meeting.
- Also appointed to Audit Committee; Board determined independent under SEC and Nasdaq rules.
- Compensation includes $50k annual retainer, $12.5k Audit Committee retainer, and annual equity grant of $440k.
- Received initial option grant of 25,538 shares with $700k grant date fair value, vesting over three years.
- Standard indemnification agreement entered into; no other arrangements or transactions requiring disclosure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017025017458/0000950170-25-017458-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017025017458/cytk-20250210.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-017458

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer